Researchers discover new therapeutic approach for cardiorenal syndrome type 2

A study suggests a new therapeutic approach to treat the development of chronic kidney disease secondary to chronic heart failure, known as cardiorenal syndrome type 2. Researchers suggest inhibiting G protein-coupled receptors (GPCR) could prevent renal damage in cardiorenal syndrome type 2 (CRS2), and could also prevent acute kidney injury (AKI).